Cantargia
Develops antibody therapies targeting IL1RAP for cancer and inflammatory diseases.
CANTA | ST
Overview
Corporate Details
- ISIN(s):
- SE0006371126 (+3 more)
- LEI:
- 549300GKWRT7RXI4VS85
- Country:
- Sweden
- Address:
- Scheelevägen 27, 223 63 Lund
- Website:
- https://cantargia.com/en/
- Sector:
- Manufacturing
Description
Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2019-06-11 16:23 | English | 34.2 KB | |||
| 2019-06-02 17:00 |
Cantargia: presentation of phase I clinical data on antibody CAN04 at ASCO
|
English | 164.7 KB | ||
| 2019-06-02 17:00 |
Cantargia: presentation på ASCO av fas I kliniska data på antikroppen CAN04
|
Swedish | 165.7 KB | ||
| 2019-05-27 18:30 |
Annual General Meeting in Cantargia AB (publ)
|
English | 81.6 KB | ||
| 2019-05-27 18:30 |
Årsstämma i Cantargia AB (publ)
|
Swedish | 29.1 KB | ||
| 2019-05-27 08:30 | Swedish | 435.1 KB | |||
| 2019-05-27 08:30 | English | 483.7 KB | |||
| 2019-05-15 23:30 |
Cantargia: sammanfattning publicerad inför den muntliga presentationen av fas I…
|
Swedish | 165.1 KB | ||
| 2019-05-15 23:30 |
Cantargia: abstract published for the oral presentation of antibody CAN04 phase…
|
English | 163.2 KB | ||
| 2019-05-14 08:30 |
Cantargia announces new pre-clinical results showing consistent positive effect…
|
English | 130.6 KB | ||
| 2019-05-14 08:30 |
Cantargia meddelar nya prekliniska resultat som genomgående visar positiva effe…
|
Swedish | 82.9 KB | ||
| 2019-05-13 08:30 |
Cantargia signs agreement with Patheon Biologics B.V. for production of antibod…
|
English | 130.5 KB | ||
| 2019-05-13 08:30 |
Cantargia ingår avtal med Patheon Biologics B.V. för produktion av antikroppen …
|
Swedish | 131.3 KB | ||
| 2019-04-30 12:30 | Swedish | 8.5 MB | |||
| 2019-04-30 08:30 |
Nytt antal aktier och röster i Cantargia
|
Swedish | 40.5 KB |
Automate Your Workflow. Get a real-time feed of all Cantargia filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cantargia
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cantargia via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-03-19 | Nedjad Losic | Other | Buy | 21,375 | 33,131.25 SEK |
| 2025-01-02 | Antonius Franciscus Berkien | Other | Other | 21,621 | 39,998.85 SEK |
| 2024-12-20 | Göran Forsberg | Other | Other | 152,206 | 281,581.10 SEK |
| 2024-12-20 | Nedjad Losic | Other | Other | 12,875 | 23,818.75 SEK |
| 2024-12-09 | Antonius Franciscus Berkien | Other | Buy | 3,741 | 6,733.80 SEK |
| 2023-01-19 | Nedjad Losic | Other | Buy | 3,918 | 29,110.74 SEK |
| 2023-01-17 | Göran Forsberg | Other | Buy | 17,000 | 140,250.00 SEK |
| 2023-01-17 | Bengt Jöndell | Other | Buy | 6,500 | 54,665.00 SEK |
| 2022-07-28 | Göran Forsberg | Other | Other | 91,765 | 344,118.75 SEK |
| 2022-07-28 | Thoas Fioretos | Other | Other | 78,400 | 294,000.00 SEK |
Peer Companies
